Thermo Fisher joins hand with Samsung for diagnostic solutions

Thermo Fisher Scientific and Samsung Electronics Ltd have formed a strategic collaboration to provide answer to the healthcare industry’s demand for better point-of-care (POC) diagnostics. The companies will jointly design, develop and market new POC solutions in key applications, such as the detection of sepsis, drugs of abuse and therapeutic drug monitoring as well as the detection of cardiac problems and women’s health conditions.
 
Marc Tremblay, president of Thermo Fisher’s clinical diagnostics business, said, “Samsung has developed a compelling and innovative suite of point-of-care platforms. We look forward to working with Samsung to add some of our leading biomarkers and assays to their platforms to create a truly differentiated testing menu.”
 
Soo-In Cho, president and head of the health & medical equipment business, Samsung, said, “We are very excited to leverage Thermo Fisher Scientific’s strong commercial sales and service channels, as well as the potential to offer a broader range of tests to our customers and their patients. This strategic collaboration combines the strengths of two industry leaders to accelerate point-of-care innovation and more rapidly bring solutions to market.”
 
According to the National Institutes of Health (NIH), POC testing enables patient diagnoses in a physician’s office; an ambulance; anywhere in the field, including a home; or in a hospital. This facilitates more rapid diagnosis and treatment.